

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities  
Exchange Act of 1934

June 12, 2019  
Date of Report (Date of earliest event reported)



**HELIUS MEDICAL TECHNOLOGIES, INC.**  
(Exact name of registrant as specified in its charter)

**DELAWARE**  
(State or other jurisdiction of  
incorporation or organization)

**001-38445**  
(Commission  
File Number)

**36-4787690**  
(I.R.S. Employer  
Identification No.)

(Exact name of registrant as specified in charter)

**642 Newtown Yardley Road, Suite 100**  
**Newtown, Pennsylvania, 18940**  
(Address of principal executive offices) (Zip Code)

**Registrant's telephone number, including area code: (215) 944-6100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a12 under the Exchange Act (17 CFR 240.14a12)
- Precommencement communications pursuant to Rule 14d2(b) under the Exchange Act (17 CFR 240.14d2(b))
- Precommencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR 240.13e4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class	Trading symbol	Name of each exchange on which registered
<b>Class A Common Stock</b>	<b>HSDT</b>	<b>The Nasdaq Stock Market LLC</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 12, 2019, Heliuss Medical Technologies, Inc. (the “*Company*”) held its 2019 annual meeting of stockholders (the “*Annual Meeting*”). The stockholders considered two proposals, each of which is described in more detail in the *Company*’s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2019. Of the 25,866,211 shares of Class A Common Stock outstanding as of the record date, 15,476,277 shares, or 59.83%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

**Proposal No. 1:** Election of seven directors of the *Company* to serve until the 2020 annual meeting of stockholders of the *Company* and until their respective successors are elected and qualified. The votes were cast as follows:

<b>Name</b>	<b>Votes For</b>	<b>Votes Withheld</b>
Philippe Deschamps	11,143,698	63,752
Dane C. Andreeff	10,930,030	277,420
Thomas E. Griffin	11,175,633	31,817
Huaizheng Peng	11,073,143	134,307
Edward M. Straw	11,149,306	58,144
Mitchell E. Tyler	11,176,198	31,252
Blane Walter	10,609,048	603,402

Broker Non-Votes: 4,268,827

All nominees were elected.

**Proposal No. 2:** Ratification of the selection of BDO USA, LLP as the *Company*’s independent registered public accounting firm for the fiscal year ending December 31, 2019. The votes were cast as follows:

	<b>Votes For</b>	<b>Votes Against</b>	<b>Abstained</b>
Ratification of Selection of BDO USA, LLP	15,429,313	14	46,950

The selection of BDO USA, LLP was ratified.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**HELIUS MEDICAL TECHNOLOGIES, INC.**

Dated: June 13, 2019

By: /s/ Joyce LaViscount  
Joyce LaViscount, Chief Financial Officer